EGFR and neoplasm: Since erlotinib always causes stronger biological effects compared to cetuximab we assume that improved tumor control by cetuximab may not be caused by cellular radiosensitization but rather by a residual immune response in the NMRI (nu/nu) mice, especially for tumors with strong EGFR expression such as UT-SCC 14-derived tumors [20, 21].